Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | PARL | Q9H300 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | BAX | Q07812 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705699 | 0.83 | NAAA (0.50) | ALDH1A1GFERALOX12NAAAIDH1 | |
| SCHEMBL2258736 | 0.83 | KMT2A (0.46) | ALDH1A1GFERALOX12NAAAPARL | |
| SCHEMBL57128 | 0.82 | PARL (0.38) | ALOX12PARLMGLLKMT2A | |
| Bicarbonate SCHEMBL28277654 | 0.80 | MGLL (0.36) | ALOX12PARLMGLLKMT2A | |
| SCHEMBL29727768 | 0.80 | AKR1C3 (0.55) | ALDH1A1PARP10FAAHKMT2AAKR1C3 | |
| SCHEMBL8530920 | 0.80 | AKR1C3 (0.55) | ALDH1A1PARP10FAAHKMT2AAKR1C3 | |
| Benzamide SCHEMBL1205196 | 0.79 | CYP2C19 (0.53) | ALOX12PARLTSHRMGLLPARP10 | |
| SCHEMBL7780925 | 0.79 | MAPK1 (0.47) | ALDH1A1ALOX12PARLMGLLKMT2A | |
| Hno SCHEMBL15321628 | 0.78 | MGLL (0.36) | ALOX12PARLMGLLKMT2A | |
| SCHEMBL15321160 | 0.78 | MGLL (0.36) | ALOX12PARLMGLLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042938-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | INDUS PHARMACEUTICALS INC (US) | 2018-02-15 | — | — | US | disclosed |
| US-9783578-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-10-10 | — | — | US | disclosed |
| US-9744175-B2 | Compositions of combinations of non-covalent DNA binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment | INDUS PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| CN-103096915-B | Immunosuppressive regulatory compounds | 奥瑞基尼探索技术有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150056192-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | INDUS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2833883-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | Indus Pharmaceuticals, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-8907053-B2 | Immunosuppression modulating compounds | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8835388-B2 | Polymer von Willebrand factor-conjugates | BAXTER INTERNATIONAL INC. (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2013151638-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | INDUS PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-8076463-B2 | Polymer-von Willebrand factor-conjugates | BAXTER INTERNATIONAL, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110111455-A1 | Polymer-Von Willebrand Factor-Conjugates | BAXTER INTERNATIONAL INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7884075-B2 | Polymer-factor VIII-von Willebrand factor-conjugates | BAXTER INTERNATIONAL INC. (US) | 2011-02-08 | — | — | US | disclosed |
| CN-101163506-A | Polymer-von willebrand factor-conjugates | BAXTER INT (US) | 2008-04-16 | — | — | CN | disclosed |
| EP-1835938-A2 | POLYMER-VON WILLEBRAND FACTOR-CONJUGATES | Baxter International Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| CN-1929860-A | Site-specific chemical modification of HIV gp41-derived peptides | TRIMERIS INC (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1734994-A1 | SITE-SPECIFIC CHEMICAL MODIFICATION OF HIV GP41-DERIVED PEPTIDES | Trimeris, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060160948-A1 | Polymer-von Willebrand factor-conjugates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| WO-2006071801-A2 | POLYMER-VON WILLEBRAND FACTOR-CONJUGATES | BAXTER INTERNATIONAL INC (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005089796-A1 | SITE-SPECIFIC CHEMICAL MODIFICATION OF HIV GP41-DERIVED PEPTIDES | TRIMERIS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042938-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | TOP2A, HMGB1, TOP2B | ALDH1A1 2433/4885GFER 4424/4885ALOX12 1112/4885 |
| US-20150056192-A1 | NOVEL COMPOSITIONS OF COMBINATIONS OF NON-COVALENT DNA BINDING AGENTS AND ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS AND THEIR USE IN DISEASE TREATMENT | TOP2A, HMGB1, TOP2B | ALDH1A1 2433/4885GFER 4424/4885ALOX12 1112/4885 |
| US-20150087581-A1 | Immunosuppression Modulating Compounds | CD274, PDCD1, PDCD1LG2 | ALDH1A1 2327/4885GFER 4611/4885ALOX12 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.